Adjuvants in tuberculosis vaccine development

FEMS Immunology and Medical Microbiology

Volumn 58, Issue 1, 2010, Pages 75-84

  Moreno Mendieta, Silvia A ^a   Rocha Zavaleta, Leticia ^a   Rodriguez Sanoja, Romina ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Adjuvant; Subunit vaccines; Tuberculosis

Indexed keywords

BCG VACCINE; LIVE VACCINE; TOLL LIKE RECEPTOR; WART VIRUS VACCINE;

BCG VACCINATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 74549199319     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2009.00629.x     Document Type: Conference Paper

References (92)

1. Agger EM, Rosenkrands I, Olsen AW et al 2006) Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24 : 5452 5460.
2. Agger EM, Rosenkrands I, Hansen J et al 2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3 : e3116 DOI :.
3. Aguilar JC Rodríguez EG (2007) Vaccine adjuvants revisited. Vaccine 25 : 3752 3762.
4. Ajdary S, Dobakhti F, Taghikhani M, Riazi-Rad F, Rafiei S Rafiee-Tehrani M (2007) Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice. Vaccine 25 : 4595 4601.
5. Aldwell FE, Cross ML, Fitzpatrick CE, Lambeth MR, de Lisle GW Buddle BM (2006) Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine 24 : 2071 2078.
6. Alving CR (2002) Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20 : S56 S64.
7. Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K Andersen P (2007) The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun 75 : 408 416.
8. Andersen P (2007) Vaccine strategies against latent tuberculosis infection. Trends Microbiol 15 : 7 13.
9. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R Crovari P (2008) Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26 : 1525 1529.
10. Badell E, Nicolle F, Clark S et al 2009) Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells. Vaccine 27 : 28 37.
11. *0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22 : 1609 1615.
12. Bivas-Benita M, Ottenhoff TH, Junginger HE Borchard G (2005) Pulmonary DNA vaccination: concepts, possibilities and perspectives. J Control Release 107 : 1 29.
13. Boog CJP (2008) Principles of vaccination and possible development strategies for rational design. Immunol Lett 122 : 122 125.
14. Boyaka PN McGhee JR (2001) Cytokines as adjuvants for the induction of mucosal immunity. Adv Drug Deliver Rev 51 : 71 79.
15. Brandt L, Skeiky YA, Alderson MR et al 2004) The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis infected guinea pigs. Infect Immun 72 : 6622 6632.
16. Brennan FR Dougan G (2005) Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 23 : 3210 3222.
17. Carpenter ZK, Williamson ED Eyles JE (2005) Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Release 104 : 67 77.
18. Carstens MG (2009) Opportunities and challenges in vaccine delivery. Eur J Pharm Sci 36 : 605 608.
19. Coucke D, Schotsaert M, Libert C, Pringels E, Vervaet C, Foreman P, Saelens X Remon JP (2009) Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine 27 : 1279 1286.
20. Csaba N, Garcia-Fuentes M Alonso MJ (2008) Nanoparticles for nasal vaccination. Adv Drug Deliver Rev 61 : 140 157.
21. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, Agger EM Andersen P (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6V-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718 : 22 31.
22. Davis SS (2001) Nasal vaccines. Adv Drug Deliver Rev 51 : 21 42.
23. de Souza Silva BD, da Silvia EB, do Nascimento IP, Guerreiro dos Reis MC, Kipnis A Junqueira-Kipnis AP (2009) MPT-51/CpG DNA vaccine protects mice against Mycobacterium tuberculosis. Vaccine 27 : 4402 4407.
24. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG Andersen P (2006) Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior Bacillus Calmette-Guerin immunity. J Immunol 177 : 6353 6360.
25. Dobakhti F, Naghibi T, Taghikhani M, Ajdary S, Rafinejad A, Bayati K, Rafiei S Refiee-Tehrani M (2009) Adjuvanticity effect of sodium alginate on subcutaneously injected BCG in BALB/c mice. Microbes Infect 11 : 296 301.
26. Doherty TM (2005) Real world TB vaccines: clinical trials in TB-endemic regions. Vaccine 23 : 2109 2114.
27. Doherty TM Andersen P (2005) Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev 18 : 687 702.
28. Doherty TM, Olsen AW, van Pinxteren L Adersen P (2002) Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 70 : 3111 3121.
29. Doherty TM, Olsen AW, Weischenfeldt J et al 2004) Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis 190 : 2146 2153.
30. D'Souza S, Rosseels V, Denis O et al 2002) Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 70 : 3681 3688.
31. Eriksson AM, Schön KM Lycke NY (2004) The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 173 : 3310 3319.
32. Eriksson K Holmgren J (2002) Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14 : 666 672.
33. Falero-Díaz G, Challacombe S, Banerjee D, Douce G, Boyd A Ivanyi J (2000) Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18 : 3223 3229.
34. Freytag LC Clements JD (2005) Mucosal adjuvants. Vaccine 23 : 1804 1813.
35. Garçon N, Chomez P Van Mechelen M (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6 : 723 739.
36. Gupta UD, Katoch VM McMurray DN (2007) Current status of TB vaccines. Vaccine 25 : 3742 3751.
37. Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5 : 505 517.
38. Haile M, Schröder U, Hamasur B, Pawlowski A, Jaxmar T, Källenius G Svenson SB (2004) Immunization with heat-killed Mycobacterium bovis Bacille Calmette-Guerin (BCG) in EurocineTM L3 adjuvant protects against tuberculosis. Vaccine 22 : 1498 1508.
39. Haile M, Hamasur B, Jaxmar T, Gavier-Widen D, Chambers MA, Sanchez B, Schröder U, Kallënius G, Svenson SB Pawlowski A (2005) Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis 85 : 107 114.
40. Hamasur B, Haile M, Pawlowski A, Schröder U, Williams A, Hatch G, Hall G, Marsh P, Källenius G Svenson SB (2003) Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 21 : 4081 4093.
41. Helgeby A, Robson NC, Donachie AM, Beackock-Sharp H, Lövgren K, Schön K, Mowat A Lycke NY (2006) The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B Cells. J Immunol 176 : 3697 3706.
42. Hoft DF (2008) Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372 : 164 175.
43. Hogarth PJ, Jahans KJ, Hecker R, Hewinson RG Chambers MA (2003) Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. Vaccine 21 : 977 982.
44. HogenEsch H (2002) Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 : S34 S39.
45. Källenius G, Pawlowski A, Brandtzaeg P Svenson SB (2007) Should a new tuberculosis vaccine be administered intranasally? Tuberculosis 87 : 257 266.
46. ® adjuvant. PLoS One 3 : e3683 DOI :.
47. Kenney RT, Rabinovich NR, Pichyangkul S, Price VL Engers HD (2002) Meeting Report. 2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Santé Fondation Mérieux, Annecy, France, 5-7 June 2000. Vaccine 20 : 2155 2163.
48. Korbel DS, Schneider BE Schaible UE (2008) Innate immunity in tuberculosis: myths and truth. Microbes Infect 10 : 995 1004.
49. Krishnamachari Y Salem AK (2009) Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliver Rev 61 : 205 217.
50. Lahiri A, Das P Chakravortty D (2008) Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26 : 6777 6783.
51. Lima KM, dos Santos SA, Rodrigues JM Silva CL (2004) Vaccine adjuvant: it makes the difference. Vaccine 22 : 2374 2379.
52. Lindblad EB, Elhay MJ, Silva R, Appelberg R Andersen P (1997) Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 65 : 623 629.
53. Lingnau K, Riedl K von Gabain A (2007) IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 6 : 741 746.
54. Maeyama J-C, Komiya T, Takahashi M, Isaka M, Goto N Yamamoto S (2009) The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid. Vaccine 27 : 1166 1173.
55. Mallapragada SK Narasimhan B (2008) Immunomodulatory biomaterials. Int J Pharm 364 : 265 271.
56. Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K May RD (2003) Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21 : 3961 3971.
57. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA Hill AVS (2005) Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 85 : 47 52.
58. Meraldi V, Audran R, Romero JF, Brossard V, Bauer J, Lopez JA Corradin G (2003) OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 21 : 2485 2491.
59. Mills KHG (2009) Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Immunol Lett 122 : 112 115.
60. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R De Gregorio E (2008) Molecular and cellular signatures of human vaccine adjuvants. P Natl Acad Sci USA 105 : 10501 10506.
61. Mutwiri G, Littel-van den Hurk SvD Babiuk LA (2009) Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv Drug Deliver Rev 61 : 226 232.
62. Okada M, Kita Y, Nakajima T et al 2009) Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 27 : 3267 3270.
63. Orme IM (2006) Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24 : 2 19.
64. Ott G Van Nest G (2007) Development of vaccine adjuvants: a historical perspective. Vaccine Adjuvants and Delivery Systems (Singh M., (ed), pp. 1 31. Wiley, Hoboken, NJ.
65. Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Fattorini L, Del Giudice G Cassone A (2008) The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-γ response. Vaccine 26 : 4237 4243.
66. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE Bramwell VW (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 364 : 272 280.
67. Quesniaux V, Fremond C, Jacobs M et al 2004) Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect 6 : 946 959.
68. Reed SG, Bertholet S, Coler RN Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30 : 23 32.
69. Rook GAW, Seah G Ustianowski A (2001) M. tuberculosis: immunology and vaccination. Eur Respir J 17 : 537 557.
70. Sable SB, Plikaytis BB Shinnick TM (2007) Tuberculosis subunit vaccine development: impact of physicochemical properties of mycobacterial test antigens. Vaccine 25 : 1153 1566.
71. Sadoff JC Hone D (2005) The role of 'go no-go' decisions in TB vaccine development. Microbes Infect 7 : 899 904.
72. Sajadi-Tabassi SA, Tafaghodi M Reza Jaafari M (2008) Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm 360 : 12 17.
73. Sanders MT, Brown LE, Deliyannis G Pearse MJ (2005) ISCOMTM-based vaccines: the second decade. Immunol Cell Biol 83 : 119 128.
74. Santosuosso M, McCormick S, Zhang X, Zganiacz A Xing Z (2006) Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 : 4634 4643.
75. Schijns VE Degen WG (2007) Vaccine immunopotentiators of the future. Clin Pharmacol Ther 82 : 750 755.
76. Schijns VEJC (2003) Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21 : 829 831.
77. ™ adjuvant. Vaccine 26 : 3209 3222.
78. Schwarz TF (2008) AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 7 : 1465 1473.
79. Sesardic D (2006) Regulatory considerations on new adjuvants and delivery systems. Vaccine 24S2 : S2/86 S2/87.
80. Sesardic D Dobbelaer R (2004) European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine 22 : 2452 2456.
81. Skeiky YA, Alderson MR, Ovendale PJ et al 2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 : 7618 7628.
82. Sun HX, Xie Y Ye YP (2009) Advances in saponin-based adjuvants. Vaccine 27 : 1787 1796.
83. Takahashi H, Sasaki K, Takahashi M, Shigemori N, Honda S, Arimitsu H, Ochi S, Ohara N Tsuji T (2006) Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus Calmette-Guerin in mice. Vaccine 24 : 3591 3598.
84. The European Medicines Agency (2005) Evaluation of Medicines for Human Use. Committee for Medicinal Products for Human Use. Guidline on Adjuvants in Vaccines for Human Use, EMEA/CHMP/VEG/134716/2004. The European Medicines Agency, London.
85. Titball RW (2008) Vaccines against intracellular bacterial pathogens. Drug Discov Today 13 : 596 600.
86. Vandepapelière P, Hormans Y, Moris P et al 2008) Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26 : 1375 1386.
87. Vollmer J Krieg AM (2009) Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliver Rev 61 : 195 204.
88. Wang J, Zganiacz A Xing Z (2002) Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine 20 : 2887 2898.
89. Williams A, Goonetilleke NP, McShane H, Clark SO, Hatch G, Gilbert SC Hill AVS (2005) Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 73 : 3814 3816.
90. World Health Organization (2009) WHO Report 2009. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO, Geneva.
91. Young D Dye C (2006) The development and impact of tuberculosis vaccines. Cell 124 : 683 687.
92. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C Dow S (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176 : 7335 7345.